Metastatic Triple-Negative Breast Cancer Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

September 10 14:00 2021
Metastatic Triple-Negative Breast Cancer Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight Business Research LLP
DelveInsight’s, “Metastatic Triple-Negative Breast Cancer (mTNBC) – Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Metastatic Triple-Negative Breast Cancer (mTNBC) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products.

DelveInsight’s “Metastatic Triple-Negative Breast Cancer Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Metastatic Triple-Negative Breast Cancer pipeline landscapes. 

The report comprises Metastatic Triple-Negative Breast Cancer pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Metastatic Triple-Negative Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Metastatic Triple-Negative Breast Cancer pipeline products.     

Some of the key takeaways from the Metastatic Triple-Negative Breast Cancer Pipeline Report:

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as HiberCell, Hoffmann-La Roche, Infinity Pharmaceuticals, CytoDyn, Treadwell Therapeutics, and others. etc., are developing therapies for the treatment of Metastatic Triple-Negative Breast Cancer.

  • Emerging therapies such as Imprime PGG, Ipatasertib, IPI-549 (Eganelisib), Leronlimab (PRO 140), Leronlimab (PRO 140), CFI-400945, are expected to have a significant impact on the  Metastatic Triple-Negative Breast Cancer market in the coming years.

Get an overview of pipeline landscape @ Metastatic Triple-Negative Breast Cancer Clinical Trials Analysis 

Metastatic Triple-Negative Breast Cancer (mTNBC) is defined as the metastatic tumor where the estrogen and progesterone (ER/PR)  are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers. 

Metastatic Triple-Negative Breast Cancer Pipeline Therapies along with Key Players:

  • Imprime PGG by HiberCell

  • IPI-549 (Eganelisib) by Hoffmann-La Roche

  • Leronlimab (PRO 140) by Infinity Pharmaceuticals

  • Leronlimab (PRO 140) by CytoDyn

  • CFI-400945 by Treadwell Therapeutics

  • And others.

Scope of Metastatic Triple-Negative Breast Cancer Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: HiberCell, Hoffmann-La Roche, Infinity Pharmaceuticals, CytoDyn, Treadwell Therapeutics, and others.

  • Pipeline Therapies: Imprime PGG, Ipatasertib, IPI-549 (Eganelisib), Leronlimab (PRO 140), Leronlimab (PRO 140), CFI-400945, and others.

Table of Contents

1

Metastatic Triple-Negative Breast Cancer Report Introduction

2

Metastatic Triple-Negative Breast Cancer Executive Summary

3

Metastatic Triple-Negative Breast Cancer Overview

4

Metastatic Triple-Negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5

Metastatic Triple-Negative Breast Cancer Pipeline Therapeutics

6

Metastatic Triple-Negative Breast Cancer Late Stage Products (Phase II/III)

7

Metastatic Triple-Negative Breast Cancer Mid Stage Products (Phase II)

8

Metastatic Triple-Negative Breast Cancer Early Stage Products (Phase I)

9

Metastatic Triple-Negative Breast Cancer Preclinical Stage Products

10

Metastatic Triple-Negative Breast Cancer Therapeutics Assessment

11

Metastatic Triple-Negative Breast Cancer Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Metastatic Triple-Negative Breast Cancer Key Companies

14

Metastatic Triple-Negative Breast Cancer Key Products

15

Metastatic Triple-Negative Breast Cancer Unmet Needs

16 

Metastatic Triple-Negative Breast Cancer Market Drivers and Barriers

17

Metastatic Triple-Negative Breast Cancer Future Perspectives and Conclusion

18

Metastatic Triple-Negative Breast Cancer Analyst Views

19

Appendix

20

About DelveInsight

Get a customized pipeline report @ Metastatic Triple-Negative Breast Cancer Drugs Pipeline Report 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/ghaziabadonline/easternindianewsmagazine.in/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7